IbogaBaseThe Iboga Evidence Base
Clinical boundary Schedule I in the U.S. Serious cardiac risk Not FDA-approved No dosing or referrals Schedule I · cardiac risk Not FDA-approved · no referrals

Review method

Methodology

How source type, confidence, claim status, correction history, and reviewer status are read across IbogaBase.

Source hierarchy

  1. Primary law, agency records, trial registries, peer-reviewed papers, and official public records.
  2. Reviews, institutional reports, books, serious journalism, conference material, and long-form interviews.
  3. Company releases, clinic pages, social posts, podcast claims, newsletters, and marketing material.
  4. Public cultural, Gabonese, Bwiti/Bwete-linked, conservation, stewardship, and community-engagement sources.

Evidence grades

High confidence

High confidence

Primary legal status, official agency records, repeated safety signals, or well-supported findings.

Moderate

Moderate

Early human studies, observational signals, registry records, reviews, or plausible claims with limitations.

Low

Low

Case reports, anecdotes, media claims, social posts, company claims, or preclinical work that needs more support.

Review status

Pages are strongest when they have medical, pharmacology, cardiology, policy/legal, and cultural review. Named reviewers are listed only with consent. Pages without named review should be read as source-compiled public reference, not expert endorsement.

Conflicts, funding, and corrections

Donations, memberships, grants, sponsorship, or paid briefs do not buy favorable coverage, clinic ranking, referral placement, treatment protocols, or miracle-claim language. Corrections update the public page and keep the source trail when possible.